Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study

dc.authorid0000-0003-2982-6108
dc.authorid0000-0002-7555-6201
dc.authorid0000-0003-0748-0839
dc.authorid0000-0003-3595-9759
dc.authorid0000-0002-8636-7174
dc.contributor.authorNarula, Neeraj
dc.contributor.authorWong, Emily C. L.
dc.contributor.authorPray, Cara
dc.contributor.authorMarshall, John K.
dc.contributor.authorRangarajan, Sumathy
dc.contributor.authorIslam, Shofiqul
dc.contributor.authorBahonar, Ahmad
dc.date.accessioned2025-05-10T19:48:51Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBACKGROUND & AIMS: Several medications have been suspected to contribute to the etiology of inflammatory bowel disease (IBD). This study assessed the association between medication use and the risk of developing IBD using the Prospective Urban Rural Epidemiology cohort.METHODS: This was a prospective cohort study of 133,137 individuals between the ages of 20 and 80 from 24 countries. Country-specific validated questionnaires documented baseline and follow-up medication use. Participants were followed up prospectively at least every 3 years. The main outcome was the development of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). Short-term (baseline but not follow-up use) and long-term use (baseline and subsequent followup use) were evaluated. Results are presented as adjusted odds ratios (aORs) with 95% CIs. RESULTS: During a median follow-up period of 11.0 years (interquartile range, 9.2-12.2 y), there were 571 incident IBD cases (143 CD and 428 UC). Incident IBD was associated significantly with baseline antibiotic (aOR, 2.81; 95% CI, 1.67-4.73; P = .0001) and hormonal medication use (aOR, 4.43; 95% CI, 1.78-11.01; P = .001). Among females, previous or current oral contraceptive use also was associated with IBD development (aOR, 2.17; 95% CI, 1.70-2.77; P < .001). Nonsteroidal anti-inflammatory drug users also were observed to have increased odds of IBD (aOR, 1.80; 95% CI, 1.23-2.64; P = .002), which was driven by long-term use (aOR, 5.58; 95% CI, 2.26-13.80; P < .001). All significant results were consistent in direction for CD and UC with low heterogeneity.CONCLUSIONS: Antibiotics, hormonal medications, oral contraceptives, and long-term nonsteroidal antiinflammatory drug use were associated with increased odds of incident IBD after adjustment for covariates.
dc.description.sponsorshipPhilippine Council for Health Research and Development; Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]; Wroclaw Medical University; Saudi Arabia: the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia [RG-1436-013]; South Africa: the North-West University; Netherlands Programme for Alternative Development, National Research Foundation; Medical Research Council of SA, The SA Sugar Association; Swedish Heart and Lung Foundation; Swedish Research Council; Swedish Council for Health, Working Life and Welfare, King Gustaf V's and Queen Victoria Freemasons Foundation; AFA Insurance; Swedish Council for Working Life and Social Research; Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning; Swedish State under the Lauml;kar Utbildnings Avtalet agreement; Sanofi Aventis, Turkey; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai United Arab Emirates
dc.description.sponsorshipSupported by the Heart & Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease (S.Y.) . The Prospective Urban Rural Epidemiology Study is an investigator-initiated study funded by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, supported by the Canadian Institutes of Health Research's Strategy for Patient Oriented Research through the Ontario Strategy for Patient Oriented Research Support Unit, as well as the Ontario Ministry of Health and Long-Term Care, and through unre-stricted grants from several pharmaceutical companies, with major con-tributions from AstraZeneca (Canada) , Sanofi-Aventis (France and Canada) , Boehringer Ingelheim (Germany and Canada) , Servier, and GlaxoSmithkline, and additional contributions from Novartis and King Pharma, and from various national or local organizations in participating countries; these include the following: Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh, and Mitra and Associ-ates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias grant 6566-04-18062; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia, grants 100-IRDC/BIOTEK 16/6/21 (13/2007) and 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia grant 600-RMI/LRGS/5/3 (2/2011) , Universiti Teknologi MARA, and Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010) ; occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, occupied Palestinian territory, International Development Research Centre, Canada; Philippines:Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education grant 290/W-PURE/2008/0, Wroclaw Medical University; Saudi Arabia: the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group RG-1436-013) ; South Africa: the North-West University, SA, and The Netherlands Programme for Alternative Development, National Research Foundation, Medical Research Council of SA, The SA Sugar Association, and Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the agreement concerning research and education of doctors, the Swedish Heart and Lung Foundation, the Swedish Research Council, the Swedish Council for Health, Working Life and Welfare, King Gustaf V's and Queen Victoria Freemasons Foundation, AFA Insurance, Swedish Council for Working Life and Social Research, Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, a grant from the Swedish State under the Laekar Utbildnings Avtalet agreement, and a grant from the Vaestra Goe taland Region; Turkey: Meta-bolic Syndrome Society, AstraZeneca, Turkey, Sanofi Aventis, Turkey; and the United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai United Arab Emirates. All authors approved the final version of the manuscript. Guarantor of the article: Neeraj Narula. r Stroke Foundation of Ontario, supported by the Canadian Institutes of Health Research's Strategy for Patient Oriented Research through the Ontario Strategy for Patient Oriented Research Support Unit, as well as the Ontario Ministry of Health and Long-Term Care, and through unre-stricted grants from several pharmaceutical companies, with major con-tributions from AstraZeneca (Canada) , Sanofi-Aventis (France and Canada) , Boehringer Ingelheim (Germany and Canada) , Servier, and GlaxoSmithkline, and additional contributions from Novartis and King Pharma, and from various national or local organizations in participating countries; these include the following: Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh, and Mitra and Associ-ates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias grant 6566-04-18062; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia, grants 100-IRDC/BIOTEK 16/6/21 (13/2007) and 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia grant 600-RMI/LRGS/5/3 (2/2011) , Universiti Teknologi MARA, and Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010) ; occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, occupied Palestinian territory, International Development Research Centre, Canada; Philippines:r Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education grant 290/W-PURE/2008/0, Wroclaw Medical University; Saudi Arabia: the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group RG-1436-013) ; South Africa: the North-West University, SA, and The Netherlands Programme for Alternative Development, National Research Foundation, Medical Research Council of SA, The SA Sugar Association, and Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the agreement concerning research and education of doctors, the Swedish Heart and Lung Foundation, the Swedish Research Council, the Swedish Council for Health, Working Life and Welfare, King Gustaf V's and Queen Victoria Freemasons Foundation, AFA Insurance, Swedish Council for Working Life and Social Research, Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, a grant from the Swedish State under the Lakar Utbildnings Avtalet agreement, and a grant from the Vastra Go taland Region; Turkey: Meta-bolic Syndrome Society, AstraZeneca, Turkey, Sanofi Aventis, Turkey; and the United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai United Arab Emirates. All authors approved the final version of the manuscript. Guarantor of the article: Neeraj Narula.
dc.identifier.doi10.1016/j.cgh.2022.11.037
dc.identifier.endpage+
dc.identifier.issn1542-3565
dc.identifier.issn1542-7714
dc.identifier.issue10
dc.identifier.pmid36528284
dc.identifier.scopus2-s2.0-85149633027
dc.identifier.scopusqualityQ1
dc.identifier.startpage2649
dc.identifier.urihttps://doi.org/10.1016/j.cgh.2022.11.037
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11846
dc.identifier.volume21
dc.identifier.wosWOS:001070331900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofClinical Gastroenterology and Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectCrohn's Disease
dc.subjectNSAIDS
dc.subjectUlcerative Colitis
dc.subjectOral Contraceptive
dc.subjectEstrogen
dc.subjectHormone
dc.subjectIBD
dc.subjectAntibiotics
dc.titleAssociations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study
dc.typeArticle

Dosyalar